Cancer Diagnostic Probe (CDP) is a real-time diagnostic system used as a complementary tool, along with Frozen and Permanent pathologies, to detect high risk cancer in the internal margins (cavity side margins) of patients undergoing breast cancer surgery. CDP detects hypoxia glycolysis immediately and quantitatively. This system with US patent ID (Pub. No: U A1, Pub. Date: Oct 18, 2018), License No: 23212882 has been introduces as a surgical assistant system in breast cancer surgery. CDP reveals the cancerous in the internal margins (cavity –side margin) within a few millimeters in 40 seconds, using a needle sensor, and has a clinical diagnostic classification matching with the pathological results of the tested tissues.
Signup today to claim your Discount. Get Started before it's too late!
